

Parasitology

Back volumes. Vols. 1–71: Inquiries should be addressed to Wm. Dawson & Sons Ltd, Cannon House, Folkestone, Kent. Vols. 72 onwards: quotations for parts still in print may be obtained from Cambridge or the American Branch of Cambridge University Press.

Copying. This journal is registered with the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923, USA. Organizations in the USA who are also registered with C.C.C. may therefore copy material (beyond the limits permitted by sections 107 and 108 of US copyright law) subject to payment to C.C.C. of the per-copy fee of \$16.00. This consent does not extend to multiple copying for promotional or commercial purposes. Code 0031–1820/2013 \$16.00.

Organizations authorized by the Copyright Licensing Agency may also copy material subject to the usual conditions.

ISI Tear Sheet Service. 3501 Market Street, Philadelphia, Pennsylvania 19104, USA, is authorized to supply single copies of separate articles for private use only.

For all other use, permission should be sought from Cambridge or the American Branch of Cambridge University Press.

Claims for missing issues can only be considered if made immediately after receipt of the subsequent issue.

Advertising. Details of advertising in Parasitology may be obtained from the publisher.

Online submission. Authors are encouraged to submit their manuscripts online. Go to <http://mc.manuscriptcentral.com/par/> to open an author's account for Parasitology. Manuscript Central is helping to improve the speed of the publication process for the journal.

Front Cover illustration: *N*-myristoyltransferase (centre, crystal structure with inhibitor bound, PDB ID 4BBH) is a promising drug target in *Leishmania* and *Plasmodium* parasites. At left: THP-1 macrophage infected with *L. major*; probed with antibodies against alpha tubulin (green) and *L. major* HASPB (red), and co-stained with DAPI (blue). Image provided by Helen Price and Deborah Smith, Centre for Immunology and Infection, Department of Biology, University of York. At right: *P. falciparum* infecting red blood cells, stained with Giemsa's reagent. Image provided by Anthony Holder, MRC National Institute for Medical Research, UK.

© Cambridge University Press 2014

The Edinburgh Building, Cambridge CB2 8RU, United Kingdom
32 Avenue of The Americas, New York, NY 10013-2473, USA
477 Williamstown Road, Port Melbourne, VIC 3207, Australia
C/ Orense, 4, Planta 13 28020 Madrid, Spain
Lower Ground Floor, Nautica Building, The Water Club, Beach Road,
Granger Bay, 8005 Cape Town, South Africa

Printed in the UK by Bell & Bain

PARASITOLOGY

CONTENTS

PREFACE: Emerging paradigms in anti-infective drug design Michael P. Barrett and Simon L. Croft	1	Animal models of efficacy to accelerate drug discovery in malaria María Belén Jiménez-Díaz, Sara Viera, Elena Fernández-Alvaro and Iñigo Angulo-Barturen	93
The utility of yeast as a tool for cell-based, target-directed high-throughput screening J. L. Norcliffe, E. Alvarez-Ruiz, J. J. Martin-Plaza, P. G. Steel and P. W. Denny	8	Pharmacokinetics and pharmacodynamics utilizing unbound target tissue exposure as part of a disposition-based rationale for lead optimization of benzoxaboroles in the treatment of Stage 2 Human African Trypanosomiasis Stephen Wring, Eric Gaukel, Bakela Nare, Robert Jacobs, Beth Beaudet, Tana Bowling, Luke Mercer, Cyrus Bacchi, Nigel Yarett, Ryan Randolph, Robin Parham, Cindy Rewerts, Jacob Platner and Robert Don	104
An <i>in silico</i> structure-based approach to anti-infective drug discovery Fraser Cunningham, Martin J. McPhillie, A. Peter Johnson and Colin W. G. Fishwick	17	Anti-<i>Wolbachia</i> drug discovery and development: safe macrofilaricides for onchocerciasis and lymphatic filariasis Mark J. Taylor, Achim Hoerauf, Simon Townson, Barton E. Slatko and Stephen A. Ward	119
Target-based drug discovery for human African trypanosomiasis: selection of molecular target and chemical matter Ian H. Gilbert	28	Antimalarial drug discovery – the path towards eradication Jeremy N Burrows, Emilie Burlot, Brice Campo, Stephanie Cherbuin, Sarah Jeanneret, Didier Leroy, Thomas Spangenberg, David Waterson, Timothy N. C. Wells and Paul Willis	128
<i>N</i>-Myristoyltransferase as a potential drug target in malaria and leishmaniasis Edward W. Tate, Andrew S. Bell, Mark D. Rackham and Megan H. Wright	37	Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections Rob Don and Jean-Robert Ioset	140
Novel inhibitors of the <i>Plasmodium falciparum</i> electron transport chain P. A. Stocks, V. Barton, T. Antoine, G. A. Biagini, S.A. Ward and P. M. O'Neill	50	Corrigendum	147
Progressing the global antimalarial portfolio: finding drugs which target multiple <i>Plasmodium</i> life stages Paul W. Smith, Thierry T. Diagana and Bryan K. S. Yeung	66	Open source drug discovery – A limited tutorial Murray N. Robertson, Paul M. Ylloja, Alice E. Williamson, Michael Woelfle, Michael Robins, Katrina A. Badiola, Paul Willis, Piero Olliaro, Timothy N. C. Wells and Matthew H. Todd	148
High-throughput decoding of drug targets and drug resistance mechanisms in African trypanosomes David Horn	77		
Determination of antiprotozoal drug mechanisms by metabolomics approaches Darren J. Creek and Michael P. Barrett	83		